# Eden Research expects a revenue increase of c. 33% and product sale up c. 54%

- Link: https://www.directorstalkinterviews.com/eden-research-expects-a-revenue-increase-of-c.33-and-product-sale-up-c.54/4121078582
- Published: 2022-08-22T07:15:35+01:00
- Author: Giles

**[Eden Research](https://www.directorstalkinterviews.com/company/eden-research-plc/eden.l)
plc** (LON:EDEN; OTCQB: EDNSF), the AIM-quoted company focused on sustainable biopesticides
and plastic-free formulation technology for use in global crop protection, animal
health and consumer products industries, provided the following unaudited trading
update for the half year to 30 June 2022.

**Highlights**

·      Revenue is expected to be c. £1.0m (H1 2021: £0.8m) an increase of c. 33%;
on track to meet full year guidance of £1.4m.

·      Product sales are expected to be c.£1.0m (H1 2021: £0.7m), an increase of
c. 54%.

·      Adjusted EBITDA (excluding Share Based Payments) is expected to be a loss
of approximately £0.8m (H1 2021: £0.8m loss), resulting in an overall loss before
tax of £1.3m (H1 2021: £1.8m loss).

·      Cash position as at 30 June balance date of £1.9m (HY 2021: £5.8m), however,
the Group had unaudited cash of £2.7m as of 15 August 2022 following a tax refund
and receipts from half-year end trade debtors.

·      Development of Eden’s seed treatment and insecticide products continue to
progress well with positive, early indications from 2022 field trials received.

·      EPA authorisation expected before year-end for Eden’s three active ingredients,
as well as Mevalone and Cedroz, allowing for meaningful sales of both products in
2023.

**Product sales growth**

Sales of Eden’s fungicide product, Mevalone, have been robust in the first half 
of the year with the impact of Covid-19 diminishing and demand for Eden’s products
returning to pre-Covid levels, despite challenging growing conditions. 

Furthermore, sales into new markets and use areas have increased as the receipt 
of product authorisations translates into sales through our distributors.  The ongoing
diversification of Eden’s product uses contributes not only to sales growth but 
an increased level of resiliency in the business as the Company expands from one
crop and disease target, to many.

**Corteva**

In May 2021, Eden signed an exclusive Commercialisation, Supply and Distribution
Agreement with Corteva Agriscience (“Corteva”), the fourth largest agriculture input
company in the world. The agreement covers Eden’s first seed treatment product which
uses Eden’s proprietary, plastic-free SustaineÒ encapsulation technology.

We have continued to work closely with Corteva and tests to date have shown initial
indications of successful trials in the current season. We are aiming to apply for
regulatory authorisation as soon as possible which, if successful, will result in
sales of the product by Eden to Corteva in time for the 2024 growing season, although
this time frame is currently an estimate and remains subject to submission of an
application for regulatory approval by the relevant authorities.

We are focused on the EU and UK as initial markets for this product, which have 
a current addressable market of €40m. In time, it is expected we will be able to
commercialise the product into other geographics, including the US, where the addressable
market is approximately €240 million. Eden estimates peak product sales arising 
from the successful development and registration of this seed treatment product 
for a specific application in all of these territories may be at least €33m per 
year.

**Insecticide**

We have started to receive, collate and review results from our own insecticide 
field trials from 2022.

In addition, samples have been sent out to a long list of third parties who are 
undertaking their own field trials in the second half of this year.

At the end of the year, we shall then review the outcome of the trials and look 
to enter into commercial arrangements with suitable, interested parties.

**EPA authorisation**

Eden awaits approval of its three active ingredients, as well as Cedroz and Mevalone,
in the US by the Environmental Protection Agency. The approvals are expected to 
significantly increase the addressable markets for Eden’s products and pave the 
way for future product authorisations based upon the registration of Eden’s three
active ingredients.

The US has one of the largest food markets in the world and its ongoing growth presents
a significant opportunity for biopesticide market participants. As the only AIM-
quoted company focused on biopesticides, we believe that Eden offers a unique proposition
for investors seeking to participate in the rapid growth and promising future of
sustainable agriculture. The EPA approval of Eden’s products, and subsequently, 
the company’s insecticide offering in the future, will open significant revenue 
opportunities for Eden, with total market potential in the region of €500 million–
approximately €94m for Mevalone, €189m for Cedroz and €237m for insecticides.

> **Sean Smith, Chief Executive Officer of Eden Research plc, commented:**
> _“The first half of the year has provided positive indications that we are on 
> track to meaningful product sales growth and we move into the second half of the
> financial year with confidence and a well-managed cash position._
> _Growing conditions may play a significant role in determining the full year’s
> results, but we are encouraged by the strong first half and the underlying demand
> for our products which these interim results represent._
> _We look forward to updating the market in due course on some of the exciting 
> projects we have in train and would like to thank shareholders for their continued
> support.”_

Share on:
